Hydroxychloroquine Dose per Ophthalmology Guidelines and the Risk of Systemic Lupus Erythematosus Flares
Authors:
Open Access
- 16 September 2022
- journal article
- letter
- Published by American Medical Association (AMA) in JAMA
- Vol. 328 (14) , 1458-1460
Abstract
Hydroxychloroquine prevents systemic lupus erythematosus (SLE) flares and is recommended for all patients with SLE.1 However, its long-term toxicity includes retinopathy, particularly at doses greater than 5 mg/kg per day.2 This dose-dependent risk led to 2016 ophthalmology guidelines3 and subsequent rheumatology recommendations1 to avoid prescribing hydroxychloroquine doses greater than 5 mg/kg per day. We assessed the association of this dose threshold on lupus flares.Keywords
This publication has 6 references indexed in Scilit:
- Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohortAnnals of the Rheumatic Diseases, 2022
- Measures of Adult Systemic Lupus Erythematosus: Disease Activity and DamageArthritis Care & Research, 2020
- 2019 update of the EULAR recommendations for the management of systemic lupus erythematosusAnnals of the Rheumatic Diseases, 2019
- Hydroxychloroquine retinopathy — implications of research advances for rheumatology careNature Reviews Rheumatology, 2018
- Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision)Ophthalmology, 2016
- Combined Oral Contraceptives in Women with Systemic Lupus ErythematosusNew England Journal of Medicine, 2005